ENTR-601-44 is intended to treat individuals with Duchenne who are exon 44 skipping amenable. Credit: hafakot / Shutterstock.

Entrada Therapeutics has received authorisation to begin a Phase I clinical trial of ENTR-601-44 in healthy volunteers to treat Duchenne muscular dystrophy in the UK.

The authorisation is granted by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for the company’s Clinical Trial of an Investigational Medicinal Product (CTIMP).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study’s primary objective is to assess the safety of a single dose of the lead product candidate ENTR-601-44 in healthy subjects, with a target enrolment of nearly 40 participants.

It will also assess pharmacokinetics, tolerability and target engagement, as measured by exon skipping in the skeletal muscle.

Entrada Therapeutics president and CEO Dipal Doshi said: “We are looking forward to this important next step in advancing ENTR-601-44 for the potential treatment of people with exon 44 skipping amenable Duchenne muscular dystrophy, where there exists a profound unmet medical need.

“This milestone, coupled with the extension of our cash runway through the end of 2025, positions Entrada to advance our Duchenne franchise while broadening the potential of our intracellular therapeutics across serious diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dosing of the first participant is anticipated in September while ENTR-601-44 study data is expected in the second half of next year.

ENTR-601-44 is an Endosomal Escape Vehicle (EEV)-conjugated phosphorodiamidate morpholino oligomer (PMO) with an oligonucleotide sequence design.

It restores the mRNA reading frame thereby allowing the translation of functional dystrophin protein that is slightly shortened.

Other lead oligonucleotide programmes of the company include ENTR-601-45 for treating Duchenne with exon 44 and 45 skipping amenable and ENTR-701 for targeting myotonic dystrophy type 1.